POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY

被引：0
|
作者：
Matasar, M. [1 ]
Herrera, A. F. [2 ]
Kamdar, M. [3 ]
Mehta, A. [4 ]
Assouline, S. [5 ]
Fleury, I. [6 ,7 ]
Kim, T. M. [8 ]
Kim, W. S. [9 ]
Bosch, F. [10 ]
Radford, J. [11 ,12 ]
Flowers, C. R. [13 ]
Bu, L. [14 ]
Hong, W. -J. [15 ]
Sehn, L. H. [16 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Univ Colorado, Denver, CO 80202 USA
[4] Univ Birmingham, Dept Med, Birmingham, W Midlands, England
[5] Jewish Gen Hosp, Montreal, PQ, Canada
[6] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[7] Univ Montreal, Montreal, PQ, Canada
[8] Seoul Natl Univ Hosp, Seoul, South Korea
[9] Samsung Med Ctr, Seoul, South Korea
[10] Hosp Univ Vall dHebron, Barcelona, Spain
[11] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[12] Christie NHS Fdn Trust, Manchester, Lancs, England
[13] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[14] Roche, Shanghai, Peoples R China
[15] Genentech Inc, San Francisco, CA 94080 USA
[16] BC Canc Agcy, Vancouver, BC, Canada
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S468
引用
收藏
页码：173 / 173
页数：1
相关论文
共 50 条
  • [1] A phase 2 study of polatuzumab vedotin plus bendamustine plus rituximab in relapsed/refractory diffuse large B-cell lymphoma
    Terui, Yasuhito
    Rai, Shinya
    Izutsu, Koji
    Yamaguchi, Motoko
    Takizawa, Jun
    Kuroda, Junya
    Ishikawa, Takayuki
    Kato, Koji
    Suehiro, Youko
    Fukuhara, Noriko
    Ohmine, Ken
    Goto, Hideki
    Yamamoto, Kazuhito
    Kanemura, Nobuhiro
    Ueda, Yasunori
    Ishizawa, Kenichi
    Kumagai, Kyoya
    Kawasaki, Atsuko
    Saito, Tomohisa
    Hashizume, Misato
    Shibayama, Hirohiko
    [J]. CANCER SCIENCE, 2021, 112 (07) : 2845 - 2854
  • [2] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    [J]. BLOOD, 2019, 134
  • [3] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    [J]. DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [4] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    [J]. HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
  • [5] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    [J]. REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [6] Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world
    Vodicka, Prokop
    Benesova, Katerina
    Janikova, Andrea
    Prochazka, Vit
    Belada, David
    Mocikova, Heidi
    Steinerova, Katerina
    Duras, Juraj
    Karban, Josef
    Hanackova, Veronika
    Sykorova, Alice
    Obr, Ales
    Trneny, Marek
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109 (02) : 162 - 165
  • [7] Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study
    Sehn, Laurie H.
    Herrera, Alex F.
    Matasar, Matthew J.
    Kamdar, Manali
    Assouline, Sarit
    Hertzberg, Mark
    Kim, Tae Min
    Kim, Won-Seog
    McMillan, Andrew
    Ozcan, Muhit
    Hirata, Jamie M.
    Penuel, Elicia
    Cheng, Ji
    Ku, Grace
    Flowers, Christopher R.
    [J]. BLOOD, 2018, 132
  • [8] Polatuzumab Vedotin in Combination with Bendamustine Plus Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Our Experience
    Darcin, Tahir
    Yigenoglu, Tugce Nur
    Sahin, Derya
    Bakirtas, Mehmet
    Basci, Semih
    Merdin, Alparslan
    Yildiz, Jale
    Ulu, Bahar Uncu
    Tetik, Aysegul
    Iskender, Dicle
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S249 - S250
  • [9] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [10] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
12345